• Blog
  • Proton Pump Inhibitors (PPIs) Market Report

    Proton Pump Inhibitors (PPIs) Market Report

    Proton Pump Inhibitors (PPIs) Market Report
    Report code - SRHL261 Delivery - 2 Weeks
    Get Free Sample |
    Play Audio
    Listen
    Global Proton Pump Inhibitors (PPIs) Market, Trends, Market Analysis
    See more...

    Impact of COVID-19 on Proton Pump Inhibitors (PPIs) Market

    Covid-19 has impacted the market dynamics, competition, and global...

    See more...

    Impact of COVID-19 on Proton Pump Inhibitors (PPIs) Market

    Covid-19 has impacted the market dynamics, competition, and global supply chain. The revenues have gone down in 2020 and may resume an uptrend gradually from 2021. Companies optimizing their operation and strategy will sustain and beat the competition.

    Note: The summary below might not have included insights on covid impact since we have large number of reports.

    Market Insights

    The Global Proton Pump Inhibitors (PPIs) Market is projected to grow from USD 2.85 billion in 2020 to USD 3.76 billion by 2026 at a CAGR of over 4.7% during the forecast period.

    Figure: Global Proton Pump Inhibitors (PPIs) Market Size, 2020-2026 (USD Billion)

    Proton-Pump-Inhibitors-(PPIs)-Market-Forecast

    Wish to get a free sample report? Click here.

    What are Proton pump initiators (PPIs)?

    Proton pump initiators (PPIs) are drugs that are primarily used for profound and prolonged reduction of stomach acid levels in individuals suffering from hyperacidity, gastroesophageal reflux disease, and ulcers.

    PPIs possess a unique mechanism of action as they are given in an inactive form that is lipophilic and readily crosses cell membranes into intracellular compartments such as the parietal cell canaliculus with an acidic environment, then the inactive drug is rearranged after protonation into its active form in an acidic environment, which irreversibly blocks the gastric proton pump of gastric parietal cells.

    Key Players

    Key players operating in the global proton pump inhibitors market are-

    • AstraZeneca PLC/AB (UK),
    • Bayer AG (Germany),
    • Pfizer Inc. (The U.S),
    • Cadila Pharmaceuticals Limited (India),
    • Eisai Pharmaceuticals India Pvt. Ltd (India),
    • Santarus, Inc. (The U.S),
    • Wyeth, LLC (The U.S),
    • Janssen Pharmaceutical (Belgium),
    • Takeda Pharmaceutical Company Limited (Japan), and
    • Sanofi S.A. (France).

    Market Dynamics

    Growing acceptance of novel drug delivery systems and increasing prevalence of peptic ulcers and other gastrointestinal disorders are some of the key factors augmenting the market growth. Rising consumer acceptance of novel drug delivery systems and new product launches offer immense growth opportunities to the market players.

    However, consumers in isolated regions tend to prefer the common antacids to deal with gastrointestinal and ulcer disorders, which is likely to hinder the product demand.

    Segment Analysis

    Drug Type Trends

    Based on drug type, the global proton pump inhibitors market has been bifurcated into over-the-counter drugs and prescription drugs.

    • The over-the-counter drugs segment is further categorized into omeprazole, lansoprazole, esomeprazole, and others.
    • Among these, the esomeprazole under the OTC drug segment garnered the highest market share in 2020 and is likely to grow at a healthy CAGR during the forecast timeline.
    • Esomeprazole is mainly indicated to treat the symptoms of heartburn, Gastroesophageal Reflux Disease (GERD), and other disorders such as excessive stomach acids, thus bolstering the segment growth.

    Regional Trends

    By region, the North American market accounted for the largest market share in 2020 and is estimated to grow at a steady CAGR during the assessment period. This can be attributed to increasing approvals of proton pump inhibitor products and the increasing prevalence of GERD in the US, Canada, and Mexico, which proliferates the industry growth in the region. Moreover, GERD affects almost 20% of adults in the US, thereby making the disease an important concern, which propels regional growth.

    COVID-19 Impact on Global Proton Pump Inhibitors (PPIs) Market

    Many scientists have found that PPIs have increased the risk of COVID-19 in patients taking these medications. In 2020, the researchers of the American Journal of Gastroenterology carried out a research in which more than 53,000 people taking PPIs participated, of which 3,386 were tested positive for COVID-19. This is likely to negatively impact the market growth as the patients undergoing PPI therapy are recommended to consume less medication and avoid these medications unless it is an emergency.

    Critical Questions Answered in the Report

    • What are the key trends in the global Proton Pump Inhibitors (PPIs) market?
    • How the market (and its various sub-segments) has grown in the last five years and what would be the growth rate in the next five years?
    • What is the impact of COVID-19 on the global Proton Pump Inhibitors (PPIs) market?
    • What are the key strategies adopted by the major vendors to lead in the global Proton Pump Inhibitors (PPIs) market?
    • What is the market share of the top vendors?

    Wish to get a customized report? Click here.

    Target Audience

    Here is the list of the group of customers that the Proton Pump Inhibitors (PPIs) market hopes to have the greatest opportunity to convert-

    • Proton Pump Inhibitors (PPIs) companies
    • Proton Pump Inhibitors (PPIs) vendors
    • Hospitals
    • Pharmaceutical companies
    • R&D organizations

    Custom Research: Stratview research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry at [email protected].

    Frequently Asked Questions (FAQs)

    The proton pump inhibitors market is expected to witness an impressive growth of 4.7% CAGR in the foreseeable future.

    AstraZeneca PLC/AB (UK), Bayer AG (Germany), Pfizer Inc. (The U.S), Cadila Pharmaceuticals Limited (India), Eisai Pharmaceuticals India Pvt. Ltd (India), Santarus, Inc. (The U.S), Wyeth, LLC (The U.S), Janssen Pharmaceutical (Belgium), Takeda Pharmaceutical Company Limited (Japan) and Sanofi S.A. (France) are among the key players in the proton pump inhibitors market.

    The proton pump inhibitors market size is expected to reach USD 3.76 billion in the coming years.

    North America accounted for the largest share of proton pump inhibitors market in 2020.

    The esomeprazole under the OTC drug segment garnered the highest share in the proton pump inhibitors market.

    Growing acceptance of novel drug delivery systems and increasing prevalence of peptic ulcers and other gastrointestinal disorders are the factors driving the growth of proton pump inhibitors market.

    Proton Pump Inhibitors (PPIs) companies, Proton Pump Inhibitors (PPIs) vendors, Hospitals, Pharmaceutical companies, R&D organizations are the target audience in the proton pump inhibitors market.

    •